These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using Yusufi N; Wurzer A; Herz M; D'Alessandria C; Feuerecker B; Weber W; Wester HJ; Nekolla S; Eiber M J Nucl Med; 2021 Aug; 62(8):1106-1111. PubMed ID: 33443072 [TBL] [Abstract][Full Text] [Related]
8. Comparison of novel PSMA-targeting [ Li L; Wang J; Wang G; Wang R; Jin W; Zang J; Sui H; Jia C; Jiang Y; Hong H; Zhu L; Alexoff D; Ploessl K; Kung HF; Zhu Z Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2794-2805. PubMed ID: 38658392 [TBL] [Abstract][Full Text] [Related]
9. Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704 [TBL] [Abstract][Full Text] [Related]
11. Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity. Deberle LM; Benešová M; Umbricht CA; Borgna F; Büchler M; Zhernosekov K; Schibli R; Müller C Theranostics; 2020; 10(4):1678-1693. PubMed ID: 32042329 [TBL] [Abstract][Full Text] [Related]
12. Preclinical Evaluation of a New Series of Albumin-Binding Boinapally S; Alati S; Jiang Z; Yan Y; Lisok A; Singh R; Lofland G; Minn I; Hobbs RF; Pomper MG; Banerjee SR Molecules; 2023 Aug; 28(16):. PubMed ID: 37630410 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic Multidose Preparation of a Ready-to-Use Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687 [No Abstract] [Full Text] [Related]
14. Enhancing Treatment Efficacy of Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544 [TBL] [Abstract][Full Text] [Related]
16. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of a Radio-IMmunoStimulant (RIMS) in a Syngeneic Model of Murine Prostate Cancer and ImmunoPET Analysis of T-cell Distribution. Śmiłowicz D; Schlyer D; Boros E; Meimetis L Mol Pharm; 2022 Sep; 19(9):3217-3227. PubMed ID: 35895995 [TBL] [Abstract][Full Text] [Related]
18. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602 [TBL] [Abstract][Full Text] [Related]
19. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer. Vlachostergios PJ; Niaz MJ; Skafida M; Mosallaie SA; Thomas C; Christos PJ; Osborne JR; Molina AM; Nanus DM; Bander NH; Tagawa ST Prostate; 2021 Apr; 81(5):279-285. PubMed ID: 33465252 [TBL] [Abstract][Full Text] [Related]